세계의 항응고제 역전제 시장

Global Anticoagulant Reversal Drugs Market to Reach US$3.0 Billion by 2030

The global market for Anticoagulant Reversal Drugs estimated at US$1.5 Billion in the year 2024, is expected to reach US$3.0 Billion by 2030, growing at a CAGR of 12.5% over the analysis period 2024-2030. Idarucizumab Drugs, one of the segments analyzed in the report, is expected to record a 14.8% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Phytonadione segment is estimated at 9.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$391.7 Million While China is Forecast to Grow at 11.6% CAGR

The Anticoagulant Reversal Drugs market in the U.S. is estimated at US$391.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$467.2 Million by the year 2030 trailing a CAGR of 11.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.8% and 10.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.9% CAGR.

Anticoagulant Reversal Drugs Market: Decoding the Trends and Future Trajectory

How Are Anticoagulant Reversal Drugs Transforming Emergency Medicine?

Anticoagulant reversal drugs have become indispensable in emergency and critical care settings, ensuring swift intervention for patients experiencing excessive bleeding due to anticoagulant therapy. These drugs counteract the effects of blood thinners such as warfarin, heparin, and direct oral anticoagulants (DOACs), reducing the risk of life-threatening hemorrhages. The rising prevalence of cardiovascular diseases and stroke has led to an increased use of anticoagulants, thereby driving demand for effective reversal agents. With newer anticoagulant classes emerging, the need for targeted and faster-acting reversal agents is becoming increasingly crucial, positioning this segment as a key component of modern medical treatment.

What Are the Key Market Drivers Behind the Growth of This Sector?

A significant driver of market expansion is the rising geriatric population, which is more susceptible to thrombotic disorders requiring anticoagulant therapy. Additionally, the growing adoption of novel oral anticoagulants (NOACs) has necessitated the development of specialized reversal drugs like andexanet alfa and idarucizumab. Regulatory support and fast-track approvals for breakthrough therapies further bolster market growth, facilitating quicker access to life-saving treatments. Moreover, increasing awareness among healthcare providers regarding the availability and efficacy of these drugs is contributing to higher adoption rates worldwide.

How Is Technology Enhancing the Development of Reversal Agents?

Advancements in biopharmaceutical research are playing a pivotal role in optimizing anticoagulant reversal agents. Cutting-edge recombinant technology has enabled the production of highly selective and effective antidotes with minimal side effects. The integration of artificial intelligence (AI) in drug discovery and clinical trials is expediting the identification of promising candidates for anticoagulation reversal. Additionally, improvements in pharmacokinetics and targeted delivery systems are ensuring that reversal agents act rapidly while minimizing potential complications, thus improving patient outcomes.

What Factors Are Propelling the Market Forward?

The growth in the anticoagulant reversal drugs market is driven by several factors, including the increasing prevalence of cardiovascular conditions, the expanding use of anticoagulant medications, and advancements in drug development technologies. The growing incidence of emergency situations requiring immediate reversal of anticoagulation effects is a key catalyst. Furthermore, heightened R&D investments by pharmaceutical companies and government initiatives aimed at improving access to critical care drugs are fostering market expansion. With ongoing innovation in biologics and small-molecule inhibitors, the market is set to witness substantial growth, driven by the urgent need for safer and more efficient reversal solutions.

SCOPE OF STUDY:

The report analyzes the Anticoagulant Reversal Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Idarucizumab Drugs, Phytonadione (Vitamin K) Drugs, Prothrombin Complex Concentrate Drugs, Andexanet Alfa Drugs, Other Drug Classes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

• AstraZeneca PLC
• Boehringer Ingelheim Pharmaceuticals, Inc.
• Bristol-Myers Squibb Company
• Cipla
• Clearsynth Lab Ltd
• Dr. Reddy's Laboratories Ltd
• Eurocrit Labs International
• Fresenius Kabi Canada Ltd.
• McKesson Medical-Surgical Inc.
• Novartis AG
• Otto Chemie Pvt. Ltd.
• Pfizer Inc.
• Shaivya Pharmachem

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Anticoagulant Reversal Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Growing Incidence of Bleeding Complications in Anticoagulated Patients Driving Demand
  • Expansion of Direct Oral Anticoagulant (DOAC) Reversal Agents Market
  • Increasing Adoption of Targeted Antidotes for Specific Anticoagulants
  • Advancements in Biologic-Based Reversal Agents for Enhanced Efficacy
  • Surge in Demand for Emergency and Hospital-Based Reversal Solutions
  • Growing Investments in Rapid-Acting and Next-Generation Reversal Therapies
  • Expansion of Clinical Trials for New Reversal Drug Candidates
  • Rising Focus on Personalized Medicine and Precision-Based Anticoagulant Reversal
  • Increasing Use of Reversal Agents in Surgical and Trauma Settings
  • Growth in Regulatory Approvals for Novel Anticoagulant Reversal Drugs
  • Surge in Public Awareness and Physician Education on Reversal Drug Applications
  • Increasing Demand for Cost-Effective and Broad-Spectrum Reversal Solutions
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Anticoagulant Reversal Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for Anticoagulant Reversal Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Idarucizumab Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for Idarucizumab Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Phytonadione by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for Phytonadione by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World 6-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 11: World 6-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 13: World 6-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Anticoagulant Reversal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 14: USA Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Drug Class - Idarucizumab Drugs and Phytonadione - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 15: USA 6-Year Perspective for Anticoagulant Reversal Drugs by Drug Class - Percentage Breakdown of Value Sales for Idarucizumab Drugs and Phytonadione for the Years 2025 & 2030
  • TABLE 16: USA Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 17: USA 6-Year Perspective for Anticoagulant Reversal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2025 & 2030
• CANADA
  • TABLE 18: Canada Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Drug Class - Idarucizumab Drugs and Phytonadione - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 19: Canada 6-Year Perspective for Anticoagulant Reversal Drugs by Drug Class - Percentage Breakdown of Value Sales for Idarucizumab Drugs and Phytonadione for the Years 2025 & 2030
  • TABLE 20: Canada Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 21: Canada 6-Year Perspective for Anticoagulant Reversal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2025 & 2030
• JAPAN
  • Anticoagulant Reversal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 22: Japan Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Drug Class - Idarucizumab Drugs and Phytonadione - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 23: Japan 6-Year Perspective for Anticoagulant Reversal Drugs by Drug Class - Percentage Breakdown of Value Sales for Idarucizumab Drugs and Phytonadione for the Years 2025 & 2030
  • TABLE 24: Japan Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 25: Japan 6-Year Perspective for Anticoagulant Reversal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2025 & 2030
• CHINA
  • Anticoagulant Reversal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 26: China Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Drug Class - Idarucizumab Drugs and Phytonadione - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 27: China 6-Year Perspective for Anticoagulant Reversal Drugs by Drug Class - Percentage Breakdown of Value Sales for Idarucizumab Drugs and Phytonadione for the Years 2025 & 2030
  • TABLE 28: China Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 29: China 6-Year Perspective for Anticoagulant Reversal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2025 & 2030
• EUROPE
  • Anticoagulant Reversal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 30: Europe Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 31: Europe 6-Year Perspective for Anticoagulant Reversal Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 32: Europe Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Drug Class - Idarucizumab Drugs and Phytonadione - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Europe 6-Year Perspective for Anticoagulant Reversal Drugs by Drug Class - Percentage Breakdown of Value Sales for Idarucizumab Drugs and Phytonadione for the Years 2025 & 2030
  • TABLE 34: Europe Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 35: Europe 6-Year Perspective for Anticoagulant Reversal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2025 & 2030
• FRANCE
  • Anticoagulant Reversal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 36: France Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Drug Class - Idarucizumab Drugs and Phytonadione - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 37: France 6-Year Perspective for Anticoagulant Reversal Drugs by Drug Class - Percentage Breakdown of Value Sales for Idarucizumab Drugs and Phytonadione for the Years 2025 & 2030
  • TABLE 38: France Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: France 6-Year Perspective for Anticoagulant Reversal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2025 & 2030
• GERMANY
  • Anticoagulant Reversal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 40: Germany Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Drug Class - Idarucizumab Drugs and Phytonadione - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 41: Germany 6-Year Perspective for Anticoagulant Reversal Drugs by Drug Class - Percentage Breakdown of Value Sales for Idarucizumab Drugs and Phytonadione for the Years 2025 & 2030
  • TABLE 42: Germany Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 43: Germany 6-Year Perspective for Anticoagulant Reversal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2025 & 2030
• ITALY
  • TABLE 44: Italy Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Drug Class - Idarucizumab Drugs and Phytonadione - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Italy 6-Year Perspective for Anticoagulant Reversal Drugs by Drug Class - Percentage Breakdown of Value Sales for Idarucizumab Drugs and Phytonadione for the Years 2025 & 2030
  • TABLE 46: Italy Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 47: Italy 6-Year Perspective for Anticoagulant Reversal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2025 & 2030
• UNITED KINGDOM
  • Anticoagulant Reversal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 48: UK Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Drug Class - Idarucizumab Drugs and Phytonadione - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 49: UK 6-Year Perspective for Anticoagulant Reversal Drugs by Drug Class - Percentage Breakdown of Value Sales for Idarucizumab Drugs and Phytonadione for the Years 2025 & 2030
  • TABLE 50: UK Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: UK 6-Year Perspective for Anticoagulant Reversal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 52: Rest of Europe Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Drug Class - Idarucizumab Drugs and Phytonadione - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 53: Rest of Europe 6-Year Perspective for Anticoagulant Reversal Drugs by Drug Class - Percentage Breakdown of Value Sales for Idarucizumab Drugs and Phytonadione for the Years 2025 & 2030
  • TABLE 54: Rest of Europe Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 55: Rest of Europe 6-Year Perspective for Anticoagulant Reversal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2025 & 2030
• ASIA-PACIFIC
  • Anticoagulant Reversal Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Drug Class - Idarucizumab Drugs and Phytonadione - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Asia-Pacific 6-Year Perspective for Anticoagulant Reversal Drugs by Drug Class - Percentage Breakdown of Value Sales for Idarucizumab Drugs and Phytonadione for the Years 2025 & 2030
  • TABLE 58: Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 59: Asia-Pacific 6-Year Perspective for Anticoagulant Reversal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2025 & 2030
• REST OF WORLD
  • TABLE 60: Rest of World Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Drug Class - Idarucizumab Drugs and Phytonadione - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 61: Rest of World 6-Year Perspective for Anticoagulant Reversal Drugs by Drug Class - Percentage Breakdown of Value Sales for Idarucizumab Drugs and Phytonadione for the Years 2025 & 2030
  • TABLE 62: Rest of World Recent Past, Current & Future Analysis for Anticoagulant Reversal Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Rest of World 6-Year Perspective for Anticoagulant Reversal Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2025 & 2030

IV. COMPETITION